Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis

Xiaorong Xu; Xuanfu Xu; Yangzong Ciren; Baisui Feng; Chunhua Tao; Yujing Xia; Zhanju Liu

Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis

Int J Clin Exp Med. 2015 Feb 15;8(2):2212-8. eCollection 2015.

Authors

Xiaorong Xu¹, Xuanfu Xu¹, Yangzong Ciren², Baisui Feng¹, Chunhua Tao¹, Yujing Xia¹, Zhanju Liu¹

Affiliations

¹ Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University No. 301 Yanchang Road, Shanghai 200072, China.
² Department of Internal Medicine, The Second People's Hospital of Tibet Autonomous Region Lhasa, China.

PMID: 25932153
PMCID: PMC4402800

Abstract

Purpose: To study the effects of 5-amino salicylic acids (5-ASAs) on the incidence rates of inflammatory bowel disease (IBD)-associated colonic cancer (IBDACa) and colonic dysplasia (IBDADys), as well as to evaluate the chemopreventive effects of 5-ASAs on IBDACa/Dys.

Methods: Searches for officially published clinical studies on the effects of 5-ASAs on the chemoprevention of IBDACa/Dys were conducted in both foreign-language databases, including PubMed (Medline), EMCC, OVID, and the Cochrane Library, and Chinese databases, including Wanfang, Weipu (VIP), and CNKI, as well as using Google Scholar. For literature matching the selection criteria, the statistical software RevMan was employed to calculate odds ratio (OR) values and 95% confidence intervals (CIs). Sub-group analysis was performed for different study design types and IBD types.

Results: A total of fourteen papers were included in this study. The results of the analysis showed that compared with patients not using 5-ASAs, patients using 5-ASAs showed only 49% of the occurrence rate of IBDACa and IBDADys, OR = 0.49 (95% CI: 0.33-0.73). The OR of ulcerative colitis (UC) patients using 5-ASAs exhibiting UCCa/Dys was 0.44 (95% CI: 0.26-0.76).

Conclusion: The use of 5-ASAs exerts a chemopreventive effect against IBDACa/Dys.

Keywords: 5-Amino salicylic acids; Crohn’s disease; chemoprevention; colon cancer; dysplasia; inflammatory bowel disease; meta-analysis; ulcerative colitis.